The Efficacy of Pramipexole, a Dopamine Receptor Agonist, as an Adjunctive Treatment in Treatment-Resistant Depression: An Open-Label Trial
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
Dopaminergic dysfunction is implicated in the pathophysiology of treatment-resistant depression. Although the efficacy of adjunctive pramipexole treatment has been demonstrated in treatment-resistant bipolar depression, such data are scarce for major depressive disorder (MDD). We recruited 17 patients with DSM-IV major depressive episode who have failed to respond to previous treatment with a selective serotonin reuptake inhibitor. Five patients were diagnosed as having bipolar II disorder and 12 as having unipolar MDD. Patients were monitored at an ambulatory care facility every two weeks until 12 weeks. Pramipexole was added to existing medication. Depression severity was assessed with the Hamilton Depression Rating Scale 21-item version (HDRS-21). The mean maximum dosage of pramipexole was 1.6 mg (SD 0.9). The HDRS-21 total score decreased from 19.4 (SD 3.8) at baseline to 7.2 (SD 5.4) at endpoint (P<0.000001). Twelve patients (71%) were responders based on the definition of 50% or more reduction in the HDRS-21 score. Ten patients (59%) remitted (HDRS-21 total score at endpoint<8). These results were almost unchanged when the sample was confined to patients with MDD. No serious adverse events were observed. Our findings indicate that pramipexole augmentation therapy may be effective and well tolerated in refractory depressed patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Open‐label studies and one controlled study showed that augmentation of antidepressants with dopamine agonist is efficacious, with the strongest evidence for pramipexole176–178.”
From Mechanisms and treatment of late-life depression (2019) · cites this paper as [177]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. (2013) · Encyclopedia of Social Work · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,519
Development of a Rating Scale for Primary Depressive Illness
HAMILTON, M. (1967) · British Journal of Social and Clinical Psychology · doi:10.1111/j.2044-8260.1967.tb00530.x · Cited by 8,410 · cited 14×
“The majority of responders demonstrated the 50% or more reduction of HDRS-21 total score within the first 4 weeks of pramipexole treatment.”
MethodInfluential(2025) · Springer Reference Medizin · doi:10.1007/978-3-662-65186-5_300379 · Cited by 1,445
A functional anatomical study of unipolar depression
Drevets, W., Videen, T., Price, J., Preskorn, S., Carmichael, S., & Raichle, M. (1992) · The Journal of Neuroscience · doi:10.1523/jneurosci.12-09-03628.1992 · Cited by 1,266 · cited 1×
“This finding provides support for a role of the central dopaminergic system in the pathophysiology of depression since cerebral metabolic activity in these regions has been found to be elevated in depression [21, 22].”
ResultThe role of dopamine in the pathophysiology of depression
Dunlop, B. W., & Nemeroff, C. B. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.3.327 · Cited by 1,244 · cited 1×
“As dopamine is involved in the regulation of motivation, volition, interest/pleasure, and attention/concentration, all of which are likely to be impaired in depressed patients, reduced dopamine neurotransmission is implicated in the pathophysiology of depression and thought to play an important role in the treatment-r…”
Background(1997) · PubMed · Cited by 727
Treatment-Resistant Depression
(2015) · Encyclopedia of Psychopharmacology · doi:10.1007/978-3-642-36172-2_200431 · Cited by 488
Goldberg, J. F., Burdick, K. E., & Endick, C. J. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.3.564 · Cited by 372 · cited 2×
“Among the latter, pramipexole, a D2/D3 receptor agonist approved for the treatment of Parkinson’s disease and restless legs syndrome, has been demonstrated to have antidepressant efficacy as an adjunctive treatment in treatment-resistant bipolar depression in two randomized placebo-controlled trials [6, 7].”
BackgroundPramipexole for bipolar II depression: a placebo-controlled proof of concept study
Zarate, C. A., Payne, J. L., Singh, J., Quiroz, J. A., Luckenbaugh, D. A., Denicoff, K. D., Charney, D. S., & Manji, H. K. (2004) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.03.013 · Cited by 347 · cited 2×
“Among the latter, pramipexole, a D2/D3 receptor agonist approved for the treatment of Parkinson’s disease and restless legs syndrome, has been demonstrated to have antidepressant efficacy as an adjunctive treatment in treatment-resistant bipolar depression in two randomized placebo-controlled trials [6, 7].”
BackgroundSporn, J., Ghaemi, S. N., Sambur, M. R., Rankin, M. A., Recht, J., Sachs, G. S., Rosenbaum, J. F., & Fava, M. (2000) · Annals of Clinical Psychiatry · doi:10.1023/a:1009060800999 · Cited by 153 · cited 2×
“This study was also supported by Grant-in-Aid for Young Scientists (Start-up) from the JSPS (H. Hori).”
BackgroundInfluential
Research works printed but not linked: 1
- 1997, Journal of Clinical Psychiatry, 58, 23
Cited by
Mechanisms and treatment of late-life depression
Alexopoulos, G. S. (2019) · Translational Psychiatry · doi:10.1038/s41398-019-0514-6 · Cited by 592
Carvalho, A. F., Berk, M., Hyphantis, T. N., & McIntyre, R. S. (2014) · Psychotherapy and Psychosomatics · doi:10.1159/000357500 · Cited by 123
Nousen, E. K., Franco, J. G., & Sullivan, E. L. (2013) · Neuroendocrinology · doi:10.1159/000355632 · Cited by 123
Biochemical markers subtyping major depressive disorder
Kunugi, H., Hori, H., & Ogawa, S. (2015) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12299 · Cited by 114
“Our group provided preclinical and clinical evidence suggesting that dopamine agonists are effective for treatment-resistant depression.(28,29) Collectively, dopamine plays an essential role in the pathophysiology of MDD and there might be a subgroup of ‘dopamine agonist-responsive depression’.”
BackgroundSelf-citationRole of Mesolimbic Brain-Derived Neurotrophic Factor in Depression
Koo, J. W., Chaudhury, D., Han, M.-H., & Nestler, E. J. (2019) · Biological Psychiatry · doi:10.1016/j.biopsych.2019.05.020 · Cited by 112
Pharmacologic approaches to treatment resistant depression: Evidences and personal experience
Tundo, A., Filippis, R. D., & Proietti, L. (2015) · World Journal of Psychiatry · doi:10.5498/wjp.v5.i3.330 · Cited by 91
Pearson-Fuhrhop, K. M., Dunn, E. C., Mortero, S., Devan, W. J., Falcone, G. J., Lee, P., Holmes, A. J., Hollinshead, M. O., Roffman, J. L., Smoller, J. W., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0093772 · Cited by 81
“Studies have also shown that dopaminergic drugs, including pramipexole, have demonstrated efficacy in the treatment of depression [12,76].”
Tundo, A., de Filippis, R., & Crescenzo, F. D. (2019) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13055 · Cited by 82
“Indeed, in observational studies pramipexole was prescribed at flexible and higher doses than in RCTs (30, 35).”
BackgroundCaldiroli, A., Capuzzi, E., Tagliabue, I., Capellazzi, M., Marcatili, M., Mucci, F., Colmegna, F., Clerici, M., Buoli, M., & Dakanalis, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222313070 · Cited by 70
Dopamine agonist‐responsive depression
Hori, H., & Kunugi, H. (2013) · Psychogeriatrics · doi:10.1111/psyg.12014 · Cited by 57
Self-citationOgawa, S., Tsuchimine, S., & Kunugi, H. (2018) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2018.08.028 · Cited by 51
Self-citationDefinition of treatment-resistant depression – Asia Pacific perspectives
Ng, C. H., Kato, T., Han, C., Wang, G., Trivedi, M., Ramesh, V., Shao, D., Gala, S., Narayanan, S., Tan, W., et al. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.11.038 · Cited by 52
Gut Microbiota and Pathophysiology of Depressive Disorder
Kunugi, H. (2021) · Annals of Nutrition and Metabolism · doi:10.1159/000518274 · Cited by 55
Self-citationOgawa, S., & Kunugi, H. (2015) · Current Neuropharmacology · doi:10.2174/1570159x13666150612225212 · Cited by 51
Self-citationAgmatine enhances antidepressant potency of MK-801 and conventional antidepressants in mice
Neis, V. B., Moretti, M., Manosso, L. M., Lopes, M. W., Leal, R. B., & Rodrigues, A. L. S. (2014) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2014.12.009 · Cited by 49
L’anhédonie dans la dépression
Gaillard, R., Gourion, D., & Llorca, P. (2013) · L Encéphale · doi:10.1016/j.encep.2013.07.001 · Cited by 45
Recent advances in dopamine D 2 receptor ligands in the treatment of neuropsychiatric disorders
Jůza, R., Musílek, K., Mezeiová, E., Soukup, O., & Korábečný, J. (2022) · Medicinal Research Reviews · doi:10.1002/med.21923 · Cited by 37
Role of Dopamine D2 Receptor in Stress-Induced Myelin Loss
Choi, M.-H., Na, J. E., Yoon, Y. R., Lee, H. J., Yoon, S., Rhyu, I. J., & Baik, J. (2017) · Scientific Reports · doi:10.1038/s41598-017-10173-9 · Cited by 33
Tundo, A., Betrò, S., de Filippis, R., Marchetti, F., Nacca, D., Necci, R., & Iommi, M. (2023) · Life · doi:10.3390/life13041043 · Cited by 37
“Currently used dopamine agonists are classified into ergot alkaloids, which can cause rare but serious adverse events such as valvular heart disease, and non-ergot alkaloids, which do not have such effects on cardiac valves [49].”
BackgroundRational site-directed pharmacotherapy for major depressive disorder
Blier, P. (2014) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145713000400 · Cited by 29
“For instance, a patient with restless leg syndrome could benefit from pramipexole on two fronts, as it is indicated for that pathology and can be effective in treatment-resistant MDD (Hori and Kunugi, 2012).”
BackgroundBerardis, D. D., Marini, S., Serroni, N., Rapini, G., Iasevoli, F., Valchera, A., Signorelli, M. S., Aguglia, E., Perna, G., Salone, A., et al. (2013) · The Scientific World JOURNAL · doi:10.1155/2013/204649 · Cited by 29
Striatal Dopamine D2/3 Receptor Availability in Treatment Resistant Depression
de Kwaasteniet, B. P., Pinto, C., Ruhé, H. G., van Wingen, G. A., Booij, J., & Denys, D. A. J. P. (2014) · PLoS ONE · doi:10.1371/journal.pone.0113612 · Cited by 26
Rota, S., Boura, I., Batzu, L., Titova, N., Jenner, P. G., Falup‐Pecurariu, C., & Chaudhuri, К. R. (2020) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2020.1806059 · Cited by 22
Qiao, H., Yang, S., Xu, C. S., Ma, X., & An, S.-C. (2019) · Stress · doi:10.1080/10253890.2019.1673361 · Cited by 22
“D2R agonists, such as pramipexole and aripiprazole, are effective in patients with depression who have failed to respond to previous medications (Choi et al., 2017; Hori & Kunugi, 2012).”
BackgroundMncube, K., Möller, M., & Harvey, B. H. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.688150 · Cited by 20
Epstein, I., Szpindel, I., & Katzman, M. A. (2014) · Psychiatry Research · doi:10.1016/s0165-1781(14)70003-4 · Cited by 23
“This suggested a unique role for pramipexole augmentation therapy as a potentially effective and well-tolerated agent in refractory depressed patients (Hori and Kunugi, 2012).”
BackgroundEvidence for reduced homovanillic acid (HVA) in the cerebrospinal fluid of patients with depression
Ogawa, S., & Kunugi, H. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.04.028 · Cited by 14
Self-citationMcAllister-Williams, H., Goudie, N., Azim, L., Bartle, V., Berger, M., Butcher, C., Chadwick, T. J., Clare, E., Courtney, P., Dixon, L., et al. (2025) · Journal of Psychopharmacology · doi:10.1177/02698811241309622 · Cited by 14
“…bipolar depression (Ashok et al., 2017) and naturalistic and open-label data (Dell’osso et al., 2013; El-Mallakh et al., 2010; Fawcett et al., 2016; Hori and Kunugi, 2012; Lattanzi et al., 2002; Perugi et al., 2001; Sporn et al., 2000) led to two small pilot randomised placebo-controlled trials…”
Aesthetic chills modulate reward learning in anhedonic depression
Jain, A., Schoeller, F., Esfand, S. M., Duda, J. M., Null, K. E., Reggente, N., Pizzagalli, D. A., & Maes, P. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.10.038 · Cited by 12
“Indeed, dopamine dysregulation is a significant factor in the pathophysiology of depression (Yadid and Friedman, 2008) and interventions targeting dopamine have shown therapeutic efficacy (Dunlop and Nemeroff, 2007; Hori and Kunugi, 2012).”
Experimental Therapeutics in Treatment-Resistant Major Depressive Disorder
Kaur, M., & Sanches, M. (2021) · Journal of Experimental Pharmacology · doi:10.2147/jep.s259302 · Cited by 12
Pramipexole Increases Go Timeouts but Not No-go Errors in Healthy Volunteers
Yang, X. Q., Glizer, D., Vo, A., Seergobin, K. N., & MacDonald, P. A. (2016) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2016.00523 · Cited by 14
“…Hornyak et al., 2014) and dystonia (Cloud and Jinnah, 2010; Jankovic, 2013), as well as potential depression (Goto et al., 2006; Papakostas, 2006; Hori and Kunugi, 2012, 2013; Howland, 2012) and addiction (Carroll et al., 1999; Streeter et al., 2005; Ohmura et al., 2011; Makhinson and…”
BackgroundPramipexole and Electroconvulsive Therapy in Treatment-Resistant Depression
Gauthier, C., Souaiby, L., Advenier-Iakovlev, E., & Gaillard, R. (2017) · Clinical Neuropharmacology · doi:10.1097/wnf.0000000000000253 · Cited by 11
Abnormal behaviours during pramipexole treatment for Cotard's syndrome: a case report
Maruo, J., Haraguchi, Y., Tateishi, H., Noguchi, T., Mizoguchi, Y., Kato, T. A., Kawashima, T., & Monji, A. (2015) · Psychogeriatrics · doi:10.1111/psyg.12148 · Cited by 11
Azim, L., Hindmarch, P. N., Browne, G., Chadwick, T. J., Clare, E., Courtney, P., Dixon, L., Duffelen, N., Fouweather, T., Geddes, J. R., et al. (2021) · BMC Psychiatry · doi:10.1186/s12888-021-03322-y · Cited by 10
Mishra, B. R., Mohapatra, D., Biswas, T., Mishra, A., Panigrahi, S., & Maiti, R. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.119891 · Cited by 7
Efficacy of Pramipexole for Treatment of Apathy in Parkinson’s Disease
Oguro, H., Kadota, K., Ishihara, M., Okada, K., & Yamaguchi, S. (2014) · International Journal of Clinical Medicine · doi:10.4236/ijcm.2014.515118 · Cited by 7
“5 mg per a day [15].”
IsHak, W. W., Meyer, A., Freire, L., Totlani, J., Murphy, N., Renteria, S., Salem, M., Chang, T., Abdelsalam, R., Khan, R., et al. (2024) · PubMed Central · Cited by 8
Dormegny-Jeanjean, L. C., Mainberger, O., de Billy, C. D. C., Obrecht, A., Dănilă, V., Erb, A., Arcay, H., Weibel, S., Blanc, F., Meyer, G., et al. (2023) · L Encéphale · doi:10.1016/j.encep.2023.01.011 · Cited by 4
From the Drugbank Application to the Novel Drugs: A Pharmacogenomic Summary
Abiyana, S. R., Santoso, S. B., Pribadi, P., Hapsari, W. S., & Syarifuddin, A. (2024) · E3S Web of Conferences · doi:10.1051/e3sconf/202450004002 · Cited by 4
“In resistant depressive individuals, pramipexole has been demonstrated to be effective and well tolerated [43].”
BackgroundMcAllister-Williams, H., Goudie, N., Azim, L., Bartle, V., Berger, M., Butcher, C., Chadwick, T. J., Clare, E., Courtney, P., Dixon, L., et al. (2024) · Health Technology Assessment · doi:10.3310/hbfc1953 · Cited by 4
Tundo, A., Betrò, S., de Filippis, R., Felici, R., Lucangeli, C., & Iommi, M. (2024) · Biomedicines · doi:10.3390/biomedicines12092064 · Cited by 3
ABSTRACTS IL SIMPÓSIO BRASILEIRO DE NEUROPSICOFARMACOLOGIA FLORIANÓPOLIS-SC 15 a 17 de maio de 2019
(2019) · Acta Neuropsychiatrica · doi:10.1017/neu.2019.38 · Cited by 3
Kunugi, H., & Tikhonova, M. A. (2022) · Progress in brain research · doi:10.1016/bs.pbr.2022.01.023 · Cited by 2
Self-citationPramipexole in Treatment Resistant Depression: A Case Review
Abdallah, N., & Kahn, J. (2023) · Pharmacology & Pharmacy · doi:10.4236/pp.2023.147016 · Cited by 1
Tundo, A., Betrò, S., de Filippis, R., Felici, R., Lucangeli, C., & Iommi, M. (2025) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001986 · Cited by 1
Dépression résistante et pramipexole : à propos de deux cas
Lejuste, F., Haroche, A., & Rabu, C. (2013) · European Psychiatry · doi:10.1016/j.eurpsy.2013.09.273
Glizer, D. (2017) · Scholarship@Western (Western University)
Tetchner, J. (2017) · Greenwich Academic Literature Archive (University of Greenwich)
Лікування хвороби Паркінсона: потенційні можливості праміпексолу пролонгованого вивільнення
Державна установа «Інститут геронтології імені Д.Ф. Чеботарьова НАМН України», К., & Карабань, І. М. (2021) · Український медичний часопис · doi:10.32471/umj.1680-3051.141.199807
Souza, R. B. D. S. (2015) · Americanae (AECID Library)
The Management of Neurocognitive Impairment in Mood Disorders
Gallagher, P., & Young, A. H. (2024) · Cambridge University Press eBooks · doi:10.1017/9781108973922.023 · Cited by 1
HEAVY METAL MUSIC, HIP-HOP MUSIC AND CONSTRUCTION NOISE INDUCES DEPRESSIVE SYMPTOMS IN MICE
Ren, J., & Lu, J. (2024) · ASEAN Journal of Psychiatry · doi:10.54615/2231-7805.47377 · Cited by 1
Azim, L., Hindmarch, P. N., Browne, G., Chadwick, T., Clare, E., Courtney, P., Dixon, L., Duffelen, N., Fouweather, T., Geddes, J. R., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14913659
Azim, L., Hindmarch, P. N., Browne, G., Chadwick, T., Clare, E., Courtney, P., Dixon, L., Duffelen, N., Fouweather, T., Geddes, J. R., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14913650
Azim, L., Hindmarch, P. N., Browne, G., Chadwick, T., Clare, E., Courtney, P., Dixon, L., Duffelen, N., Fouweather, T., Geddes, J. R., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14913647
Azim, L., Hindmarch, P. N., Browne, G., Chadwick, T., Clare, E., Courtney, P., Dixon, L., Duffelen, N., Fouweather, T., Geddes, J. R., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14913686
Azim, L., Hindmarch, P. N., Browne, G., Chadwick, T., Clare, E., Courtney, P., Dixon, L., Duffelen, N., Fouweather, T., Geddes, J. R., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14913662
Azim, L., Hindmarch, P. N., Browne, G., Chadwick, T., Clare, E., Courtney, P., Dixon, L., Duffelen, N., Fouweather, T., Geddes, J. R., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14913674
Azim, L., Hindmarch, P. N., Browne, G., Chadwick, T., Clare, E., Courtney, P., Dixon, L., Duffelen, N., Fouweather, T., Geddes, J. R., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14913644
Azim, L., Hindmarch, P. N., Browne, G., Chadwick, T., Clare, E., Courtney, P., Dixon, L., Duffelen, N., Fouweather, T., Geddes, J. R., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14913656
Azim, L., Hindmarch, P. N., Browne, G., Chadwick, T., Clare, E., Courtney, P., Dixon, L., Duffelen, N., Fouweather, T., Geddes, J. R., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14913665
Azim, L., Hindmarch, P. N., Browne, G., Chadwick, T., Clare, E., Courtney, P., Dixon, L., Duffelen, N., Fouweather, T., Geddes, J. R., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14913677
Azim, L., Hindmarch, P. N., Browne, G., Chadwick, T., Clare, E., Courtney, P., Dixon, L., Duffelen, N., Fouweather, T., Geddes, J. R., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14913638
Azim, L., Hindmarch, P. N., Browne, G., Chadwick, T., Clare, E., Courtney, P., Dixon, L., Duffelen, N., Fouweather, T., Geddes, J. R., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14913683
Azim, L., Hindmarch, P. N., Browne, G., Chadwick, T., Clare, E., Courtney, P., Dixon, L., Duffelen, N., Fouweather, T., Geddes, J. R., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14913641
Mahmud, A., & Efremov, L. (2026) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2026.1948686
Metadata
- Authors
- Hori, H., & Kunugi, H.
- Affiliations
- National Center of Neurology and Psychiatry (JP)
- Corresponding author
- Kunugi, Hiroshi
- Venue
- The Scientific World Journal
- Publisher
- Wiley
- Published
- 2012
- Volume
- 2012
- Pages
- 1-8
- ISSN
- 1537-744X (ISSN-L)
- PMC
- PMC3415165
- OpenAlex
- W2108580074
- Cited by
- 62
- References
- 22
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 6 · 2023: 3 · 2022: 2 · 2021: 19 · 2020: 1 · 2019: 6 · 2018: 2 · 2017: 2 · 2016: 1 · 2015: 4 · 2014: 6 · 2013: 6
- FWCI
- 3.76
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- The Scientific World JOURNAL (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Institutional Repositories DataBase (IRDB) (submittedVersion)
- Funders
- Health and Labor Sciences Research Grants
- Mitsubishi Pharma Research Foundation
- CREST
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- pramipexole, dopamine agonists, treatment-resistant depression, major depressive disorder, bipolar II disorder, adjunctive therapy, augmentation therapy, dopaminergic dysfunction, remission, adverse events
- MeSH terms
- Pramipexole, Adult, Depression, Female, Humans, Male, Middle Aged, Dopamine Agonists, Benzothiazoles
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
